Introducing the new Spruson & Ferguson brand
Today, Spruson & Ferguson is proud to unveil our new brand. Our new brand builds on our position as a market leader in intellectual property services, and defines what will...
Today, Spruson & Ferguson is proud to unveil our new brand. Our new brand builds on our position as a...
Read More
The 2023 IP year in review, and predictions for 2024
In Australia, February signals a return from the beach, children back to school after a long summer break and of course the usual traffic woes! At Spruson & Ferguson Lawyers,...
In Australia, February signals a return from the beach, children back to school after a long summer break and...
Read More
What the High Court Decision in Aristocrat means for patent owners
The High Court of Australia issued a split decision in Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents on 17 August 2022. As reported in our previous article,...
The High Court of Australia issued a split decision in Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents...
Read More
Pfizer preliminary discovery attempt on ERELZI fails
In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice Burley finding that undertakings provided by Sandoz to give notice...
In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice...
Read More
Pfizer suffers setback in ENBREL battle
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application against Sandoz was dismissed by Justice Burley in the Federal...
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application...
Read More
TGA transparency reforms (part 2): Early publication of major innovator prescription medicine applications
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to provide early confidential notification to innovators of applications under evaluation...
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to...
Read More
TGA transparency reforms (part 1): Notification of generic and biosimilar medicines to impact pharmaceutical patent disputes in Australia
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation is conducted in Australia. The Therapeutic Goods Administration (TGA) is...
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation...
Read More
“Promising” development for ESCO Corporation
ESCO Corporation v Ronneby Road Pty Ltd FCAFC 46 We previously reported the Federal Court decision in Ronneby Road Pty Ltd v ESCO Corporation  FCA 588  in which all claims...
ESCO Corporation v Ronneby Road Pty Ltd FCAFC 46 We previously reported the Federal Court decision in Ronneby Road Pty...
Read More

Contact our Expert Team

Contact Us
Contact Us